Drug intelligence / Profile preview

methylphenidate transdermal system

Development stage
Approved
Lead developer
Noven Pharmaceuticals
Modality
Small Molecules
Administration
Transdermal
01

Overview

Methylphenidate transdermal system is a patch formulation used to treat Attention Deficit Hyperactivity Disorder (ADHD). It's a central nervous system stimulant that works by increasing levels of natural brain chemicals like norepinephrine and dopamine, which play important roles in attention, focus, and impulse control. This medication is used as part of a comprehensive treatment program that also includes social, educational, and psychological interventions. The patch delivers medication through the skin over a 9-hour period and comes in four different strengths: 10 mg/9 hours (1.1 mg/hr), 15 mg/9 hours (1.6 mg/hr), 20 mg/9 hours (2.2 mg/hr), and 30 mg/9 hours (3.3 mg/hr). It's designed to be applied to the hip area 2 hours before an effect is needed and removed after 9 hours, though it can be removed earlier if a shorter duration of effect is desired.

Brand names
Daytrana
Other names
methylphenidate patchmethylphenidate transdermal
02

Targets

DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on methylphenidate transdermal system.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylphenidate transdermal system.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call